DS 1040

Drug Profile

DS 1040

Alternative Names: DS-1040; DS-1040b

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Cardiovascular therapies
  • Mechanism of Action Carboxypeptidase U inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pulmonary embolism; Stroke

Most Recent Events

  • 01 Sep 2016 Phase-I/II clinical trials in Pulmonary embolism (Adjunctive treatment, In adults, In the elderly) in USA (IV) (NCT02923115)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke(In volunteers) in Japan (IV, Infusion)
  • 01 Jun 2016 Daiichi Sankyo completes a phase I trial in Healthy volunteers in United Kingdom (NCT02647307)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top